Max Robotics — Global Service Robot Directory + US Certification

About

Masatsugu Hamaji is a thoracic surgeon and researcher whose work bridges the frontiers of immunotherapy and surgical oncology, with a particular focus on non-small cell lung cancer (NSCLC). His most impactful contribution, a 2024 study on salvage surgery following immune checkpoint inhibitor (ICI) therapy for initially unresectable NSCLC, has already garnered 6 citations, highlighting its timely relevance. This work addresses a critical gap in the field: defining the role and outcomes of surgical intervention after ICIs have rendered tumors resectable, offering new hope for patients with advanced disease. Beyond lung cancer, Hamaji has explored the technical challenges of robotic surgery, as seen in his 2020 study on left-side DaVinci™ procedures, and has contributed to the understanding of rare mediastinal tumors, such as paratracheal thymic carcinomas. His research is characterized by a practical, patient-centered approach, tackling both high-volume clinical questions and niche surgical challenges. For students and researchers, Hamaji’s work exemplifies how modern thoracic surgery is evolving to integrate cutting-edge immunotherapy with traditional operative techniques, making him a key figure in the personalized treatment of thoracic malignancies.